ArticleMolecular and cellular biology1997
Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor.
Article in Molecular and cellular biology, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 155 citations in OpenAlex.
- Using different zebrafish models to explore liver regeneration.Frontiers in cell and developmental biology · 2024Review
- Article
- Proline oxidase silencing inhibits p53-dependent apoptosis in MCF-7 breast cancer cells.Amino acids · 2021Article
- The Epstein-Barr virus deubiquitinating enzyme BPLF1 regulates the activity of topoisomerase II during productive infection.PLoS pathogens · 2021Article
- 3,6-Disubstituted 1,2,4-Triazolo[3,4-OncoTargets and therapy · 2020Article
- Mutual regulation of MDM4 and TOP2A in cancer cell proliferation.Molecular oncology · 2019Article
- A systematic review and meta-analysis of topoisomerase inhibition in pre-clinical glioma models.Oncotarget · 2018Article
- Article
- PTEN stabilizes TOP2A and regulates the DNA decatenation.Scientific reports · 2015Article
- Review
- Functional interaction between cyclooxygenase-2 and p53 in response to an endogenous electrophile.Redox biology · 2015Article
- Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells.Cell death & disease · 2013Article
- P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.Diagnostic pathology · 2013Article
- Endonuclease G interacts with histone H2B and DNA topoisomerase II alpha during apoptosis.Molecular and cellular biochemistry · 2012Article
- Dietary isothiocyanate-induced apoptosis via thiol modification of DNA topoisomerase IIα.The Journal of biological chemistry · 2011Article
- Expression and amplification of Topoisomerase-2α in type 1 and type 2 papillary renal cell carcinomas and its correlation with HER2/neu amplification.Pathology oncology research : POR · 2011Article
- One function--multiple mechanisms: the manifold activities of p53 as a transcriptional repressor.Journal of biomedicine & biotechnology · 2011Review
- Topoisomerase II alpha is required for embryonic development and liver regeneration in zebrafish.Molecular and cellular biology · 2009Article
- HMGB1 and HMGB2 proteins up-regulate cellular expression of human topoisomerase IIalpha.Nucleic acids research · 2009Article
- Valproic acid induces p21 and topoisomerase-II (alpha/beta) expression and synergistically enhances etoposide cytotoxicity in human glioblastoma cell lines.Journal of neuro-oncology · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
DNA topoisomerase II (topo II) is an essential nuclear enzyme involved in major cellular functions such as DNA replication, transcription, recombination, and mitosis. While an elevated level of topo II alpha is associated with cell proliferation, wild-type (wt) p53 inhibits the expression of various growth-stimulatory genes. To determine if p53 downregulates topo II alpha gene expression, a murine cell line, (10)1val, that expresses a temperature-sensitive p53 was utilized. The (10)1val cells had significantly lower levels of topo II alpha mRNA and protein following incubation for 24 h at 32 degrees C (p53 with wt conformation) than at 39 degrees C (p53 with mutant conformation). The effect of p53 on the human topo II alpha gene promoter was determined by using luciferase reporter plasmids containing varying lengths of the topo II alpha promoter transiently cotransfected into p53-deficient (10)1 cells together with wt or mutant p53 expression plasmids. Transcription from the full-length (bp -557 to +90) topo II alpha promoter was decreased 15-fold by wt p53 in a concentration-dependent manner, whereas mutant p53 exerted much weaker inhibition. Consecutive deletion of the five inverted CCAAT elements (ICEs) from the topo II alpha promoter reduced both the basal promoter activity and wt p53-induced suppression. Transcription of the minimal promoter (-32 to +90), which contains no ICE, was slightly stimulated by wt or mutant p53 expression. When point mutations were introduced into the most proximal ICE (-68), the inhibitory effect of wt p53 was alleviated and stimulation of topo II alpha expression resulted. Our study suggests that wt p53 functions as a transcriptional repressor of topo II alpha gene expression, possibly through a functional interaction with specific ICEs. Inactivation of wt p53 may reduce normal regulatory suppression of topo II alpha and contribute to abortive cell cycle checkpoints, accelerated cell proliferation, and alterations in genomic stability associated with neoplasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.